InxMed (Nanjing), a clinical-stage biopharma focusing on developing "Best-in-Disease Combination" medicines, completed a $19 million Series A+ round. InxMed's major project, IN10018, is an active ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor. According to InxMed,  IN100018 overcame drug resistance faced by KRAS G12C inhibitors in preclinical tests. The company is conducting clinical trials of IN10018 in the US, Australia and China for four indications. The financing was led by Ennovation Ventures and China Growth Capital with InnoMed Capital and Grand Yangtze Capital participating. More details.... Share this with colleagues: // //